Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion

Siya Zhang^{1,2,#}, Hongyin Wang^{3,#}, Zhongwen Chen⁴, Ilya Levental³, Xubo Lin^{1,5,*}

1. Institute of Single Cell Engineering, Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing 100191, China.
2. Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China.
3. Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22903, USA.
4. Multiscale Research Institute of Complex Systems, Fudan University, Shanghai 200433, China.
5. Key Laboratory of Ministry of Education for Biomechanics and Mechanobiology, School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China.

* Correspondence to: linxbseu@buaa.edu.cn (XL)

These authors contribute equally to this work.

Abstract

Recently identified palmitoylation of PD-L1 is essential for immune regulation. To elucidate the underlying molecular mechanism, we performed giant plasma membrane vesicle (GPMV) experiments, μ s-scale all-atom molecular dynamics (MD) simulations and immune killing experiments. GPMV experiments indicated that PD-L1 palmitoylation enhanced its lipid raft affinity. MD simulations revealed dramatically different membrane orientation states of PD-L1 in liquid-ordered (L_o , lipid raft) compared to liquid-disordered (L_d , non-raft) membrane environments. L_d region promoted the “lie-down” orientation of PD-L1, which could inhibit its association with the PD-1 protein on immune cells and thus promote the immune killing of cancer cells. This hypothesis was supported by immune killing experiments using $\gamma\delta$ T cells as effector cells and NCI-H1299 lung cancer cells as target cells. In short, our study demonstrates that the palmitoylation affects PD-L1’s membrane localization and then membrane orientation, which thus regulates its binding with T cell PD-1 and the immune regulation. These observations may guide therapeutic strategies by explicating the regulation of immune checkpoint proteins by post-translational modifications and membrane environments.

Keywords: PD-L1 Palmitoylation; Raft Affinity; Membrane Orientation; Cancer Immunotherapy; Simulations and Experiments

Introduction

In the past decades, cancer immunotherapy experienced unprecedented development in both the fundamental and clinical researches, revolutionizing the future of cancer treatment^[1-2]. Among these approaches, immune checkpoint proteins such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have attracted great attention^[3-4]. When PD-L1 on cancer cell

membranes attaches to PD-1 on T cell membranes, it can effectively inhibit killing of cancer cells by T cells^[5-7]. Hence, blocking binding between PD-L1 and PD-1 has become an effective way to boost the cancer-killing ability of T cells^[8-9]. Especially, high-resolution structures of PD-1 and PD-L1 complex^[10] have stimulated the rapid development of various drugs including antibodies^[11], peptides^[12], small molecules^[13] and nanomedicines^[14] to directly block their binding. Also, the transfection of the PD-1 gene into cancer cells with highly expressing PD-L1 can also recover the immune responses of T cells^[15]. This is because on the surface of cancer cells the expressed PD-1 can directly bind to PD-L1, which makes the membrane orientation of PD-L1 not suitable to attach PD-1 on T cell membranes. In other words, the membrane orientation thermodynamics of cancer cell PD-L1 is essential for their binding to T cell PD-1 and thus the immune regulation.

As shown in **Fig. 1a**, the full-length PD-L1 consists of an extracellular portion (position 19-238), a single α -helical transmembrane domain (position 239-259), and the cytoplasmic domain (position 260-290). The extracellular domain can be further divided into two functional Ig-like domains: V-type (position 19-127) and C2-type (position 133-225). Recently, Yang *et al.*^[16] identified a single palmitoylation modification site in its cytoplasmic domain at Cys272 with bioinformatics tools^[17]. Palmitoylation is the covalent attachment of palmitic acid to typically cysteine (S-palmitoylation) of membrane proteins, which usually locates at the cytosolic part of the protein close to the inner cell membrane. They further found that site-specific mutation of the palmitoylation site or inhibition of the relevant palmitoyltransferase (ZDHHC9) could disrupt PD-L1 palmitoylation and restore T-cell killing ability to two kinds of breast cancer cells. This well validated the role of the palmitoylation in regulating PD-L1 stability and thus the immune response of T cells. Concomitantly, Yao *et al.*^[18] concluded a similar role of PD-L1 palmitoylation in regulating T-cell immune responses against cancer cells, via reduced ubiquitination of PD-L1 and escape from the subsequent degradation, which is regulated by electrostatic interactions between the cytoplasmic domain and the cell membrane^[19]. While the impact of PD-L1 palmitoylation in immune regulation is validated, the potential impact of PD-L1 palmitoylation on its binding to PD-1 is still not clear.

One of the well-known roles for palmitoylation of transmembrane proteins is to enhance their affinity to lipid rafts^[20-23], which are nanoscale functional ordered membrane domains^[24]. Because membrane orientation of transmembrane proteins can be modulated by the surrounding membrane lipid compositions^[25-27], we speculate that PD-L1 palmitoylation may promote its lipid raft affinity and thereby affect its membrane orientation, potentially affecting immune responses by modulating its interaction with PD-1. To test this hypothesis, we first performed giant plasma membrane vesicle (GPMV) experiments for wild-type PD-L1 (WT) and a palmitoylation-null mutant (C272A) to confirm the role of palmitoylation in determining PD-L1's lipid raft affinity. Then, all-atom molecular dynamics (MD) simulations were used to reveal the relationship between membrane lipid composition and PD-L1's membrane orientation. Last, we validated the implication from MD simulations via immune killing experiments using $\gamma\delta T$ cells and PD-L1 highly expressed NCI-H1299 lung cancer cells.

Methods

Giant Plasma Membrane Vesicle Experiments. GPMVs formation and K_p measurement were performed as previously described^[28-29]. Briefly, MDA-MB-231 cells were transfected with PD-L1-GFP

(Addgene #121139) or PD-L1-GPF-C272A. Then GPMVs were induced by incubating cells in GPMV buffer (150 mM NaCl, 10mM HEPES, 2mM CaCl₂, 2 mM N-ethylmaleimide, pH 7.4) at 37°C for 3 h. To facilitate phase separation, 200 uM DCA (sodium deoxycholic acid) was added to the GPMV solution. Annexin V Alexa Fluor® 647 (AV647, ThermoFisher, #A23204; 1:100 dilution) was used to label non-raft regions on phase separated GPMVs. After cooling to <10 °C using Peltier stage (Warner Instruments), phase separated GPMVs were imaged using the epifluorescence microscope. The raft partitioning coefficient (K_p) was calculated as $K_p = (I_{L_o} - I_0)/(I_{L_d} - I_0)$. I_{L_o} and I_{L_d} are the intensities in the protein channel from raft (AV647 poor) and non-raft (AV647 rich) regions. I_0 is the background intensity from the protein channel.

Molecular Dynamics Simulations. In our simulations, full-length PD-L1 without the signal peptide (position 19-290, **Fig. S1**) was used. Currently, the crystal structure for the transmembrane domain of PD-L1 is not available. The structure of its extracellular domain (PDB ID: 4Z18, 1.95 Å) is stable and conserved, while the cytoplasmic domain (PDB ID: 6L8R) is very flexible. Considering this, we employed the I-TASSER webserver^[30] using the crystal structure of PD-L1's extracellular domain (PDB ID: 4Z18) as a template to obtain the full-length structure of PD-L1 (**Fig. S1**). In the current work, the liquid-ordered (L_o) lipid membrane of PSM/POPC/Chol (0.61/0.08/0.31) and the liquid-disordered (L_d) lipid membrane of PSM/POPC/Chol (0.23/0.69/0.08)^[31-32] were adopted to model the lipid raft and non-raft membrane domains in all all-atom MD simulations (PSM: palmitoylsphingomyelin, POPC: 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine, Chol: cholesterol). CHARMM-GUI^[33-34] was employed to set up simulation systems of PD-L1 with or without palmitoylation embedded in L_o or L_d lipid membranes correspondingly. L_o membrane system consists of one palmitoylated PD-L1, 244 PSM, 32 POPC, 124 Chol, 47736 TIP3 waters, 150 mM NaCl, and its initial box dimension is 9.65nm×9.65nm×20.02nm. L_d membrane system consists of one PD-L1 without palmitoylation, 92 PSM, 276 POPC, 32 Chol, 58754 TIP3 waters, 150 mM NaCl, and its initial box dimension is 10.71nm×10.71×19.78nm.

CHARMM36m all-atom force field^[35] with grid-based energy correction maps for the protein conformational refinement^[36] and GROMACS 2019.6^[37] were used for all our MD simulations. We chose “cutoff” scheme for the Lennard-Jones potential, which was smoothly shifted to zero between 1.0 and 1.2 nm to reduce cutoff noise. Particle mesh Ewald electrostatics with a real-space cutoff of 1.2 nm was used. PD-L1, lipids and water&ions were coupled separately to Nose-Hoover heat baths^[38-39] with the coupling constant of 1 ps for T = 310 K. Pressure was kept at 1 bar using a semiisotropic Parrinello-Rahman coupling scheme^[40] with a coupling constant of 5 ps and a compressibility of 4.5×10^{-5} bar⁻¹. LINCS algorithm was used to constrain bonds with hydrogen atoms. The nonbonded interaction neighbor list was updated every 20 steps with a cutoff of 1.2 nm. The simulations were run for 2 μs with the time step of 2 fs. System snapshots were rendered by VMD^[41].

In order to quantify the membrane orientation thermodynamics of PD-L1, we obtained the two-dimensional (2D) Gibbs free energy map with two reaction coordinates based the MD trajectories using the equation $\Delta G = -RT \ln(\Omega/\Omega_0)$, where R is the gas constant (8.31 J·K⁻¹·mol⁻¹) and Ω is the density of states. One reaction coordinate (ξ_1) is the center-of-mass distance along the membrane normal (z axis) between the distal sub-domain of PD-L1 (position 19-127, **Fig. 1a**) and the lipid membrane, while the

other reaction coordinate (ξ_2) represents the center-of-mass z-distance between the adjacent sub-domain of PD-L1 (position 133-225, **Fig. 1a**) and the lipid membrane. These two reaction coordinates can be directly calculated using GROMACS tool *gmx distance*^[37] over the MD trajectories.

Human Peripheral Blood Mononuclear Cells Isolation and $\gamma\delta$ T Cell Expansion. In order to obtain high-purity $\gamma\delta$ T cells, we first collected peripheral blood samples from healthy volunteers with informed consent, which were approved by the ethical board of the Institute of Basic Medical Sciences at the Chinese Academy of Medical Sciences. Then, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque (Pharmacia, Sweden) density gradient centrifugation and cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% FBS and 200 IU/ml recombinant human interleukin-2 (IL-2) (Beijing Four Rings Biopharmaceutical, China), 5 μ M zoledronate acid (CTTQ Pharma, China). After 9 days of culture, $\gamma\delta$ T cells of a purity >80% was used for the subsequent immune killing experiments.

Cancer Cell Lines and Culture. NCI-H1299 human non-small cell lung cancer cells with high expression of PD-L1 were purchased from the American Type Culture Collection (ATCC) and cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) at 37 °C in humidified 5% CO₂. Trypsin (0.25%) EDTA (0.02%) solution (BI, Israel) was used for cell passage. Methyl- β -cyclodextrin (MBCD) was purchased from sigma Aldrich (USA) and used to extract cholesterol from NCI-H1299 cells according to the state-of-art protocol^[42].

Flow Cytometry and Antibodies. In order to make sure the sufficient interactions of PD-1 and PD-L1 for our $\gamma\delta$ T cells and NCI-H1299 cancer cells, flow cytometry was performed to detect the proportions of the expressions of PD-1 as well as $\gamma\delta$ TCR for $\gamma\delta$ T cells and of PD-L1 for NCI-H1299 cells. For cell surface staining, the $\gamma\delta$ T cells and NCI-H1299 cancer cells were incubated with antibodies FITC anti-human gamma delta TCR (Clone B1.1, eBioscienceTM, USA), PE/DazzleTM 594 anti-human PD-1 (CD279, Clone EH12.2H7, Biolegend, CA, USA), mouse anti-human PD-L1 (primary antibody, CD273, Clone OTI9E12, ORIGENE, MD, USA) and APC goat anti-mouse IgG (secondary antibody, Clone Poly4053, Biolegend, CA, USA) respectively for 30 min at 4 °C. Then, the cells were analyzed with ACEA NovoCytTM (ACEA Biosciences, CA, USA), and the data were analyzed by NovoExpress software (ACEA Biosciences, CA, USA).

In Vitro Cytotoxic Assay. NCI-H1299 cells as target cells were added to 96-well plates at a density of 5 $\times$ 10⁵ per well. The expanded $\gamma\delta$ T cells as effector cells were incubated with target cells at an effector-to-target ratio of 5:1 and 10:1 overnight, and each condition was plated in quadruplicate. The three controls were background group, spontaneous release group and maximal release group. We detected the cytotoxicity by a lactate dehydrogenase (LDH) assay using the Cytotox 96 non-radioactive cytotoxicity assay kit (Promega, USA) according to the kit instructions. Cytotoxicity was calculated using the following formula:

$$\text{Cytotoxicity (\%)} = \frac{(\text{Experimental release} - \text{Spontaneous release})}{(\text{Total release} - \text{Spontaneous release})} \times 100$$

For each $\gamma\delta$ T cells sample, the cytotoxicity of $\gamma\delta$ T cells to NCI-H1299 cells treated with 0 mM, 1.25 mM or 2.5 mM MBCD are tested at least five times for each effector-to-target ratio. Considering individual differences in immunity, the relative killing efficiency was calculated by normalizing the cytotoxicity value with the average cytotoxicity value of 0 mM MBCD.

Figure 1. Palmitoylation promotes PD-L1's lipid raft affinity. (a) Schematic of functional domains and palmitoylation site for full-length PD-L1 (290 aa). (b) The partitioning of wild-type (WT) and mutant (C272A) full-length PD-L1 in GPMVs. AV647 is a fluorescent probe for non-raft domain. Scale bar: 2μm. (c) K_p value for wild-type and mutant PD-L1.

Results and Discussion

Palmitoylation Promotes PD-L1's Lipid Raft Affinity. Multiple cancer cell lines including MDA-MB-231 were used in several independent experiments to validate the role of PD-L1 palmitoylation in the immune regulation [16, 18]. Hence, in this work, we use MDA-MB-231 cells for our GPMV experiments to test whether PD-L1 palmitoylation affects its lipid raft affinity. For this purpose, we transfected wild-type (WT) and mutant (C272A) PD-L1 with a GFP tag into MDA-MB-231 cells and quantified their raft affinity in GPMVs. As shown in **Fig. 1b-c**, PD-L1 (green) is enriched in the liquid disordered membrane domain (marked by AV647), though with clear signal in the raft phase. Compared to WT PD-L1, the C272A mutant is nearly entirely excluded from the raft domain. Quantification of K_p indicated that palmitoylation indeed significantly enhanced the lipid raft affinity of PD-L1, which is consistent with our previous results for other transmembrane proteins (e.g. LAT - Linker for activation of T-cells)[20-21, 43]. Since the protein-lipid interactions play key roles in determining the dynamics and functions of proteins, the significant differences in lipid compositions for lipid raft and non-raft domains may induce dramatic different membrane dynamics of PD-L1, which could be important for its functions. However, it was worth mention that PD-L1 both with and without palmitoylation mainly resides in the lipid non-raft domain, which is different from LAT[21, 43]. This is probably due to the position differences of the palmitoylation site relative to the transmembrane domain of the protein. For the case of PD-L1, Cys272 is relative far from the transmembrane domain (**Fig. 1a**), which thus have the limited effects in determining the final lipid raft affinity of the protein.

Figure 2. Membrane composition determines the orientation thermodynamics of PD-L1's extracellular domain. (a) 2D free energy maps for the membrane orientation thermodynamics of PD-L1's extracellular domain in L_o and L_d lipid membranes. "S" and "L" represents "stand-up" and "lie-down" states respectively. (b) Representative conformations indicated in Fig. 2a. PD-L1 is shown as cartoon and colored according to its secondary structure, while its palmitoylation is visualized in *vdW* beads. PSM, POPC and Chol are colored as light red, green and blue beads.

Lipid Raft Affinity Determines PD-L1 Membrane Orientation Thermodynamics. GPMV experiments revealed that PD-L1 palmitoylation significantly enhanced its lipid raft affinity, with depalmitoylated PD-L1 being completely excluded from raft domains. To investigate the possible structural consequences of this difference, we performed μ s-scale all-atom MD simulations of PD-L1 in two membrane systems. One system is L_o lipid membrane embedded with a palmitoylated PD-L1, the other system is L_d lipid membrane embedded with a PD-L1 without palmitoylation. Three-component lipid membranes were used to simulate L_o (PSM/POPC/Chol = 0.61/0.08/0.31) and L_d (PSM/POPC/Chol = 0.23/0.69/0.08) lipid membranes^[31-32], which provides insights for the lipid raft and non-raft membrane domains with complex lipid compositions.

Considering the importance of protein's membrane orientations in the binding between PD-1 (immune cells) and PD-L1 (cancer cells)^[10], we mainly focused on the differences of PD-L1's membrane orientation thermodynamics in L_o and L_d lipid membranes. For this purpose, the center-of-mass distances along z axis between two sub-domains (position 19-127, position 133-225, Fig. 1a) of PD-L1 and the lipid membrane were chosen as the two reaction coordinates (ξ_1 , ξ_2). States of these two reaction coordinates were recorded in real time over the whole 2 μ s all-atom MD simulations (Fig. S2). Using the equation $\Delta G = -RT \ln(\Omega/\Omega_0)$ and the highest density of states as Ω_0 , we could obtain

the corresponding 2D free energy maps (Fig. 2a). The system configurations for typical states in Fig. 2a were shown in Fig. 2b. We could clearly find that the probabilities for the “stand-up” (“S”) and “lie-down” (“L”) states of PD-L1 are dramatically different in L_o lipid membrane from those in L_d lipid membrane. Generally, when palmitoylated PD-L1 (PD-L1-Pal) reside in L_o lipid membrane, it can have more “stand-up” states, which likely facilitate the engagement between cancer cell PD-L1 and T cell PD-1. For L_d lipid membrane, de-palmitoylated PD-L1 (PD-L1-noPal) possesses more “lie-down” states, which are not likely to allow PD-1/PD-L1 binding. Besides, the transition between “stand-up” and “lie-down” states is relatively easier for palmitoylated PD-L1 in L_o lipid membrane. In order to highlight the role of lipid compositions, we also studied the membrane orientation thermodynamics of de-palmitoylated PD-L1 in L_o lipid membrane. As shown in Fig. S3, de-palmitoylated PD-L1 showed even much more preference to the “stand-up” states. This indicates that the surrounding lipid compositions play key roles in determining the preference to different membrane orientation conformations of PD-L1, and the presence of the palmitoylation can promote the transition between “stand-up” and “lie-down” states (Figs. 2a and S3).

Figure 3. The absence of PD-L1’s transmembrane and cytoplasmic domains induces dramatically different orientation thermodynamics of its extracellular domain. (a) The transmembrane and cytoplasmic domains of PD-L1 are truncated and replaced with a lipid anchor (palmitoylation). The truncated PD-L1 is then placed in L_o and L_d lipid membranes **for quantify** its orientation thermodynamics transitioning between “stand-up” (S, multicolor) and “lie-down” (L, gray). **(b)** 2D free energy maps for the membrane orientation thermodynamics of truncated PD-L1 in L_o and L_d lipid membranes.

Different lipid compositions can induce different membrane orientation conformation of both

membrane-bound^[26] and transmembrane proteins^[27]. However, the mechanisms underlying these effects are often unclear. To determine whether direct interactions between lipids and the extra-membrane domain of PD-L1 was essential to the conformational distributions we observed, we simulated only the extracellular part of PD-L1 (position 19-235), which was anchored to the membrane via an ectopic C-terminal lipid anchor (palmitoylation at P235C). We then placed this truncated PD-L1 close to L_o or L_d lipid membranes, with the lipid anchor inserted into the membrane. The two new membrane systems were simulated for 1 μ s and the corresponding 2D membrane orientation free energy maps are shown in (Fig. 3). While interactions between the extracellular domain of PD-L1 and L_o/L_d membrane lipids have some effects on the transitions between various states, the PD-L1 extra-membrane domain behaved significantly different from the full-length PD-L1 (Fig. 2). Truncated PD-L1 could experience both “stand-up” and “lie-down” states easily both in L_o and L_d lipid membranes. Thus, considering the flexibility of the cytoplasmic domain of PD-L1, we propose that the significant effects of lipid environment on PD-L1’s membrane orientation thermodynamics (Figs. 2 and 3) probably originate from the transmembrane domain of PD-L1.

Figure 4. Removal of cholesterol molecules from cancer cells enhances the killing efficiency of immune cells. (a) Schematics of immune killing experiments based on immune checkpoint proteins PD-1 and PD-L1. (b) Flow cytometry analyzing the expression of PD-L1 in NCI-H1299 lung cancer cells. Number above the bracketed line indicates percent PD-L1⁺ cells. (c) Flow cytometry analyzing the expression of PD-1 and $\gamma\delta$ TCR in $\gamma\delta$ T cells. Numbers in quadrants indicate percent cells in each throughout. (d) Relative killing efficiency of $\gamma\delta$ T cells over NCI-H1299 lung cancer cells with the treatment of MBDCD of different concentrations with the effector-to-target ratio of 5:1.

Cholesterol Depletion from Cancer Cells Promotes $\gamma\delta$ T Cell Killing Efficiency. PD-L1 palmitoylation promotes its lipid raft affinity and changes its membrane orientation thermodynamics. PD-L1 in lipid

raft domain can access the “stand-up” state easier than in non-raft domain. Thus, we hypothesized that palmitoylation/raft association would promote the binding of PD-1 and PD-L1 and thereby suppress cytotoxicity of immune cells against cancer cells. Since cholesterol is required for lipid rafts, we tested the effects of lipid rafts on PD-L1 function by depleting membrane cholesterol from cancer cells via methyl-beta cyclodextrin (MBCD). We chose NCI-H1299 lung cancer cells and $\gamma\delta$ T cells to perform immune killing experiments (**Fig. 4a**). $\gamma\delta$ T cells have the advantage of tissue tropism and early activation, especially the intrinsic immune-like MHC non-restrictive recognition, allowing them to directly recognize a broad spectrum of tumor-associated antigens and exert cytotoxic activity. NCI-H1299 cells have a relatively high expression of PD-L1^[44] (**Fig. 4b**), while $\gamma\delta$ T cells will have sufficient expressions of PD-1 and $\gamma\delta$ TCR under the stimulation of cancer cells^[45-47] (**Fig. 4c**). MBCD was used to extract cholesterol molecules from NCI-H1299 cancer cell membranes. It is suggested that the MBCD concentration not higher than 3 mM is suitable for deleting cholesterol without significantly reducing the viability of cells^[42]. Hence, we tested the situations of 0 mM, 1.25 mM and 2.5 mM MBCD in our immune killing experiments. These three cases are supposed to have increased cholesterol deleting ability. For the quantification of the killing efficiency of $\gamma\delta$ T cells to NCI-H1299 cells, LDH assay was used. As shown in **Fig. 4d** and **Fig. S5**, the killing efficiency of $\gamma\delta$ T cells to NCI-H1299 cells treated with 2.5 mM MBCD is significantly enhanced for all the tested samples. In other words, deleting the cholesterol of NCI-H1299 cells can recover the immune killing ability of $\gamma\delta$ T cells, which is consistent with and can be elucidated by the results of our MD simulations. The cell membrane will change from cholesterol-rich (L_o -like) to cholesterol-poor (L_d -like) by deleting the cholesterol. PD-L1 in the L_d -like cell membrane prefers the “lie-down” state, which inhibits the binding of PD-1 with PD-L1 and thus promote the immune normalization.

Scheme 1. Two key roles of PD-L1 palmitoylation in the immune regulation: (1) PD-L1 palmitoylation inhibits its ubiquitination and the corresponding ubiquitin-dependent protein degradation (orange part)^[18]. (2)

PD-L1 palmitoylation enhances its lipid raft affinity and changes its membrane orientation thermodynamics, which promotes its binding with PD-1 and thus suppresses the immune responses of $\gamma\delta$ T cells (This work).

Conclusions

In this work, we proposed a new physical mechanism for the roles of PD-L1 palmitoylation in immune regulation by a combination of cellular experiments and atomistic simulations (**Scheme 1**). GPMV experiments confirmed that PD-L1 palmitoylation enhanced the protein's lipid raft affinity. μ s-scale all-atom MD simulations then revealed the membrane orientation thermodynamics of PD-L1 extracellular domain in L_o and L_d lipid membranes, indicating that PD-L1 in L_d lipid membranes prefers the “lie-down” state, which we hypothesized would inhibit the binding of PD-1 with PD-L1, thus inhibiting immune suppression. This was validated in immune killing experiments of $\gamma\delta$ T cells to NCI-H1299 lung cancer cells whose membrane cholesterol were depleted using MBCD. In short, roles of PD-L1 palmitoylation in the immune regulation can be summarized in two points (**Scheme 1**). On the one hand, PD-L1 palmitoylation can prevent the ubiquitination and its subsequent protein degradation process^[18]. On the other hand, PD-L1 palmitoylation can enhance its lipid raft affinity (**Fig. 1**) and the probability of the “stand-up” membrane orientation state (**Figs. 2**), which thus promote the binding of PD-1 with PD-L1 and suppress the killing of immune cells to cancer cells (**Fig. 4**).

Supporting Information

Additional supplementary figures.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 21903002, XL), the Fundamental Research Funds for the Central Universities (No. YWF-20-BJ-J-632, XL), the Open Fund of State Key Laboratory of Membrane Biology (No. 2020KF09, XL) and US National Institutes of Health/National Institute of General Medical Sciences (R35 GM134949, R01 GM124072, IL). We are grateful to Center for High Performance Computing of Beihang University (BHHPCC) for generous computing resources.

References:

- [1] Mellman, I.; Coukos, G.; Dranoff, G. Cancer Immunotherapy Comes of Age. *Nature* **2011**, *480*, 480-489.
- [2] Waldman, A. D.; Fritz, J. M.; Lenardo, M. J. A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice. *Nat. Rev. Immunol.* **2020**, *20*, 651-668.
- [3] Topalian, S. L.; Drake, C. G.; Pardoll, D. M. Targeting the Pd-1/B7-H1(Pd-L1) Pathway to Activate Anti-Tumor Immunity. *Curr. Opin. Immunol.* **2012**, *24*, 207-212.
- [4] Chen, L.; Han, X. Anti-Pd-1/Pd-L1 Therapy of Human Cancer: Past, Present, and Future. *J. Clin. Invest.* **2015**, *125*, 3384-3391.
- [5] Okazaki, T.; Chikuma, S.; Iwai, Y.; Fagarasan, S.; Honjo, T. A Rheostat for Immune Responses: The Unique Properties of Pd-1 and Their Advantages for Clinical Application. *Nat. Immunol.* **2013**, *14*, 1212-8.

- [6] Peng, Q., et al. Pd-L1 on Dendritic Cells Attenuates T Cell Activation and Regulates Response to Immune Checkpoint Blockade. *Nat. Commun.* **2020**, *11*, 4835.
- [7] Chen, G., et al. Exosomal Pd-L1 Contributes to Immunosuppression and Is Associated with Anti-Pd-1 Response. *Nature* **2018**, *560*, 382-386.
- [8] Sanmamed, M. F.; Chen, L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. *Cell* **2018**, *175*, 313-326.
- [9] Ribas, A.; Wolchok, J. D. Cancer Immunotherapy Using Checkpoint Blockade. *Science* **2018**, *359*, 1350-1355.
- [10] Zak, K. M.; Grudnik, P.; Magiera, K.; Domling, A.; Dubin, G.; Holak, T. A. Structural Biology of the Immune Checkpoint Receptor Pd-1 and Its Ligands Pd-L1/Pd-L2. *Structure* **2017**, *25*, 1163-1174.
- [11] Andrews, L. P.; Yano, H.; Vignali, D. A. A. Inhibitory Receptors and Ligands Beyond Pd-1, Pd-L1 and Ctl4-4: Breakthroughs or Backups. *Nat. Immunol.* **2019**, *20*, 1425-1434.
- [12] Li, C.; Zhang, N.; Zhou, J.; Ding, C.; Jin, Y.; Cui, X.; Pu, K.; Zhu, Y. Peptide Blocking of Pd-1/Pd-L1 Interaction for Cancer Immunotherapy. *Cancer Immunol. Res.* **2018**, *6*, 178-188.
- [13] Wu, Q.; Jiang, L.; Li, S.-c.; He, Q.-j.; Yang, B.; Cao, J. Small Molecule Inhibitors Targeting the Pd-1/Pd-L1 Signaling Pathway. *Acta Pharmacol. Sin.* **2021**, *42*, 1-9.
- [14] Coronel, M. M., et al. Immunotherapy Via Pd-L1–Presenting Biomaterials Leads to Long-Term Islet Graft Survival. *Sci. Adv.* **2020**, *6*, eaba5573.
- [15] Zhao, Y.; Harrison, D. L.; Song, Y.; Ji, J.; Huang, J.; Hui, E. Antigen-Presenting Cell-Intrinsic Pd-1 Neutralizes Pd-L1 in Cis to Attenuate Pd-1 Signaling in T Cells. *Cell Rep.* **2018**, *24*, 379-390 e6.
- [16] Yang, Y., et al. Palmitoylation Stabilizes Pd-L1 to Promote Breast Tumor Growth. *Cell Res.* **2019**, *29*, 83-86.
- [17] Ren, J.; Wen, L.; Gao, X.; Jin, C.; Xue, Y.; Yao, X. Csp-Palm 2.0: An Updated Software for Palmitoylation Sites Prediction. *Protein Eng. Des. Sel.* **2008**, *21*, 639-644.
- [18] Yao, H., et al. Inhibiting Pd-L1 Palmitoylation Enhances T-Cell Immune Responses against Tumours. *Nat. Biomed. Eng.* **2019**, *3*, 306-317.
- [19] Wen, M., et al. Pd-L1 Degradation Is Regulated by Electrostatic Membrane Association of Its Cytoplasmic Domain. *Nat. Commun.* **2021**, *12*, 5106.
- [20] Levental, I.; Lingwood, D.; Grzybek, M.; Coskun, Ü.; Simons, K. Palmitoylation Regulates Raft Affinity for the Majority of Integral Raft Proteins. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 22050-22054.
- [21] Lorent, J. H.; Diaz-Rohrer, B.; Lin, X.; Spring, K.; Gorfe, A. A.; Levental, K. R.; Levental, I. Structural Determinants and Functional Consequences of Protein Affinity for Membrane Rafts. *Nat. Commun.* **2017**, *8*, 1219.
- [22] Lin, X.; Gorfe, A. A.; Levental, I. Protein Partitioning into Ordered Membrane Domains: Insights from Simulations. *Biophys. J.* **2018**, *114*, 1936-1944.
- [23] Gök, C.; Plain, F.; Robertson, A. D.; Howie, J.; Baillie, G. S.; Fraser, N. J.; Fuller, W. Dynamic Palmitoylation of the Sodium-Calcium Exchanger Modulates Its Structure, Affinity for Lipid-Ordered Domains, and Inhibition by Xip. *Cell Rep.* **2020**, *31*, 107697.
- [24] Sezgin, E.; Levental, I.; Mayor, S.; Eggeling, C. The Mystery of Membrane Organization: Composition, Regulation and Roles of Lipid Rafts. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 361-374.

- [25] Prakash, P.; Zhou, Y.; Liang, H.; Hancock, J. F.; Gorfe, A. A. Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis. *Biophys. J.* **2016**, *110*, 1125-1138.
- [26] Li, Z.-L.; Buck, M. Computational Modeling Reveals That Signaling Lipids Modulate the Orientation of K-Ras4a at the Membrane Reflecting Protein Topology. *Structure* **2017**, *25*, 679-689.e2.
- [27] Polley, A.; Orłowski, A.; Danne, R.; Gurtovenko, A. A.; Bernardino de la Serna, J.; Eggeling, C.; Davis, S. J.; Róg, T.; Vattulainen, I. Glycosylation and Lipids Working in Concert Direct Cd2 Ectodomain Orientation and Presentation. *J. Phys. Chem. Lett.* **2017**, *8*, 1060-1066.
- [28] Sezgin, E.; Kaiser, H.-J.; Baumgart, T.; Schwille, P.; Simons, K.; Levental, I. Elucidating Membrane Structure and Protein Behavior Using Giant Plasma Membrane Vesicles. *Nat. Protoc.* **2012**, *7*, 1042-1051.
- [29] Levental, K. R.; Levental, I., Isolation of Giant Plasma Membrane Vesicles for Evaluation of Plasma Membrane Structure and Protein Partitioning. In *Methods in Membrane Lipids*, Owen, D. M., Ed. Springer New York: New York, NY, 2015; pp 65-77.
- [30] Roy, A.; Kucukural, A.; Zhang, Y. I-Tasser: A Unified Platform for Automated Protein Structure and Function Prediction. *Nat. Protoc.* **2010**, *5*, 725-738.
- [31] Sodt, A. J.; Sandar, M. L.; Gawrisch, K.; Pastor, R. W.; Lyman, E. The Molecular Structure of the Liquid-Ordered Phase of Lipid Bilayers. *J. Am. Chem. Soc.* **2014**, *136*, 725-732.
- [32] Sodt, Alexander J.; Pastor, Richard W.; Lyman, E. Hexagonal Substructure and Hydrogen Bonding in Liquid-Ordered Phases Containing Palmitoyl Sphingomyelin. *Biophys. J.* **2015**, *109*, 948-955.
- [33] Lee, J., et al. Charmm-Gui Input Generator for Namd, Gromacs, Amber, Openmm, and Charmm/Openmm Simulations Using the Charmm36 Additive Force Field. *J. Chem. Theory Comput.* **2016**, *12*, 405-413.
- [34] Wu, E. L., et al. Charmm-Gui Membrane Builder toward Realistic Biological Membrane Simulations. *J. Comput. Chem.* **2014**, *35*, 1997-2004.
- [35] Huang, J.; Rauscher, S.; Nawrocki, G.; Ran, T.; Feig, M.; de Groot, B. L.; Grubmüller, H.; MacKerell, A. D. Charmm36m: An Improved Force Field for Folded and Intrinsically Disordered Proteins. *Nat. Methods* **2017**, *14*, 71-73.
- [36] Best, R. B.; Zhu, X.; Shim, J.; Lopes, P. E. M.; Mittal, J.; Feig, M.; MacKerell, A. D. Optimization of the Additive Charmm All-Atom Protein Force Field Targeting Improved Sampling of the Backbone ϕ , Ψ and Side-Chain X1 and X2 Dihedral Angles. *J. Chem. Theory Comput.* **2012**, *8*, 3257-3273.
- [37] Abraham, M. J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J. C.; Hess, B.; Lindahl, E. Gromacs: High Performance Molecular Simulations through Multi-Level Parallelism from Laptops to Supercomputers. *SoftwareX* **2015**, *1-2*, 19-25.
- [38] Nosé, S. A Molecular Dynamics Method for Simulations in the Canonical Ensemble. *Mol. Phys.* **1984**, *52*, 255-268.
- [39] Hoover, W. G. Canonical Dynamics: Equilibrium Phase-Space Distributions. *Phys. Rev. A* **1985**, *31*, 1695-1697.
- [40] Parrinello, M.; Rahman, A. Polymorphic Transitions in Single Crystals: A New Molecular Dynamics Method. *J. Appl. Phys.* **1981**, *52*, 7182-7190.
- [41] Humphrey, W.; Dalke, A.; Schulten, K. Vmd: Visual Molecular Dynamics. *J. Mol. Graph.* **1996**, *14*,

33-38.

- [42] Mahammad, S.; Parmryd, I., Cholesterol Depletion Using Methyl- β -Cyclodextrin. In *Methods in Membrane Lipids*, Owen, D. M., Ed. Springer New York: New York, NY, 2015; pp 91-102.
- [43] Diaz-Rohrer, B. B.; Levental, K. R.; Simons, K.; Levental, I. Membrane Raft Association Is a Determinant of Plasma Membrane Localization. *Proc. Natl. Acad. Sci. U.S.A.* **2014**, *111*, 8500-8505.
- [44] Li, T.; Hu, Z.; Wang, C.; Yang, J.; Zeng, C.; Fan, R.; Guo, J. Pd-L1-Targeted Microbubbles Loaded with Docetaxel Produce a Synergistic Effect for the Treatment of Lung Cancer under Ultrasound Irradiation. *Biomater. Sci.* **2020**, *8*, 1418-1430.
- [45] Rossi, C., et al. Boosting $\Gamma\delta$ Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Pd-1 Blockade in Follicular Lymphoma. *OncolImmunology* **2019**, *8*, 1554175.
- [46] Iwasaki, M.; Tanaka, Y.; Kobayashi, H.; Murata-Hirai, K.; Miyabe, H.; Sugie, T.; Toi, M.; Minato, N. Expression and Function of Pd-1 in Human $\Gamma\delta$ T Cells That Recognize Phosphoantigens. *Eur. J. Immunol.* **2011**, *41*, 345-355.
- [47] Sheng, Y.; Chen, K.; Jiang, W.; Wu, Z.; Zhang, W.; Jing, H.; Wang, L.; Qu, C.; Ren, H. Pd-1 Restrains IL-17a Production from $\Gamma\delta$ T Cells to Modulate Acute Radiation-Induced Lung Injury. *Transl. Lung Cancer Res.* **2021**, *10*, 685-698.

TOC Graphics

PD-L1 palmitoylation regulates immune responses of T cells via changing its membrane orientation.

Supporting Information for

Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion

Siya Zhang^{1,2,#}, Hongyin Wang^{3,#}, Zhongwen Chen⁴, Ilya Levental^{3,*}, Xubo Lin^{1,5,*}

1. Institute of Single Cell Engineering, Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing 100191, China.
2. Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China.
3. Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22903, USA.
4. Multiscale Research Institute of Complex Systems, Fudan University, Shanghai 200433, China.
5. Key Laboratory of Ministry of Education for Biomechanics and Mechanobiology, School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China.

FTVTVPKDLVVEYGSNMTIECKFPVEKQLDLAA
LIVYWEMEDKNIIQFVHGEEEDLKVQHSSYRQRAR
LLKDQLSLGNAALQITDVKLQDAGVYRCMISYGG
ADYKRITVKVNAPYNKINQRILVVDPTSEHELT
CQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREE
KLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTA
ELVIPELPLAHPPNERTHLVILGAILLCLGVALT
FIFRLRKGRMMDVKK**CG**IQDTNSKKQSDTHLEET

Figure S1. Amino acid sequence for full-length PD-L1 (left) and its corresponding molecular configuration (right). The palmitoylation site is shown in bold.

Figure S2. Time evolution of membrane orientation of full-length PD-L1 in L_o (PD-L1-Pal) and L_d (PD-L1-noPal) lipid membranes.

Figure S3. 2D free energy map (a) and time evolution (b) of membrane orientation of PD-L1 without palmitoylation in L_o lipid membrane.

Figure S4. Time evolution of membrane orientation of PD-L1 without TMD in L_o and L_d lipid membranes.

Figure S5. Relative killing efficiency of $\gamma\delta$ T cells over NCI-H1299 lung cancer cells with the treatment of MBCD of different concentrations with the effector-to-target ratio of 10:1.